诱导免疫化疗联合同步放化疗对比单纯同步放化疗治疗局限期小细胞肺癌:多中心倾向评分匹配分析
该多中心回顾性研究纳入2021年1月至2024年7月接受根治性放化疗的局限期小细胞肺癌患者,比较联合或不联合诱导免疫化疗的疗效与安全性。倾向评分匹配前后,诱导免疫化疗组的总生存和无进展生存均显著优于单纯放化疗组,且两组不良事件无显著差异。
要点
- 诱导免疫化疗后根治性放化疗较单纯放化疗显著改善总生存和无进展生存。
- 匹配后2年总生存率70.4%对50.1%,2年无进展生存率45.0%对25.4%。
- 两组不良事件无显著差异,未增加毒性。
核心结论
- 对于局限期小细胞肺癌,在根治性放化疗前加入诱导免疫化疗可显著改善临床结局且不增加毒性。
研究设计与样本
- 多中心回顾性研究纳入2021年1月至2024年7月接受根治性放化疗的局限期小细胞肺癌患者372例,其中单纯放化疗组275例,诱导免疫化疗后放化疗组97例,采用倾向评分匹配控制混杂因素。
主要发现
- 匹配前,单纯放化疗组中位总生存30.3个月,诱导免疫化疗组未达到,2年总生存率59.4%对72.2%(P=0.006)。
- 匹配前,中位无进展生存12.0个月对22.5个月,2年无进展生存率27.1%对47.5%(P<0.001)。
- 1:1倾向评分匹配后,单纯放化疗组中位总生存24.4个月,诱导免疫化疗组未达到,2年总生存率50.1%对70.4%(P=0.002)。
- 匹配后,中位无进展生存11.8个月对21.9个月,2年无进展生存率25.4%对45.0%(P=0.001)。
- 两组不良事件无显著差异。
临床怎么用
- 对于局限期小细胞肺癌,可考虑在根治性放化疗前给予诱导免疫化疗以改善生存,且不增加毒性。
局限性
- 本研究为多中心回顾性研究,尽管采用倾向评分匹配,仍可能存在未控制的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study is to evaluate the efficacy and safety of induction immunochemotherapy before definitive chemoradiotherapy (CRT) in patients with limited-stage small-cell lung cancer (LS-SCLC). MATERIALS AND METHODS: This multicenter retrospective study included patients with LS-SCLC treated with definitive CRT, with or without induction immunochemotherapy from January 2021 to July 2024. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Propensity score matching (PSM) was applied to control potential confounders. Survival was analyzed with Kaplan-Meier method and log-rank tests, and Cox regression was employed for prognostic analysis. RESULTS: Overall, 372 patients were included: 275 received definitive CRT alone (CRT group) and 97 received induction immunochemotherapy followed by definitive CRT (I-CRT group). Before PSM, the median OS was 30.3 months in the CRT group vs. not reached (NR) in the I-CRT group, with a 2-year OS of 59.4% vs. 72.2% (P = 0.006). The median PFS was 12.0 months vs. 22.5 months, with a 2-year PFS of 27.1% vs. 47.5%, respectively (P < 0.001). After 1:1 PSM, the median OS was 24.4 months in the CRT group vs. NR in the I-CRT group, with a 2-year OS of 50.1% vs. 70.4% (P = 0.002). The median PFS was 11.8 months vs. 21.9 months, with a 2-year PFS of 25.4% vs. 45.0%, respectively (P = 0.001). There were no significant differences in adverse events between the two groups. CONCLUSION: For LS-SCLC, the addition of induction immunochemotherapy to definitive CRT significantly improves clinical outcomes without increasing toxicity.
引用
- Hou X, Guo Y, Yan M, et al. Induction immunochemotherapy before definitive chemoradiotherapy versus definitive chemoradiotherapy alone in limited-stage small-cell lung cancer: a multicenter propensity score-matched analysis. Radiat Oncol. 2026. PMID: 41808131. doi:10.1186/s13014-026-02819-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。